Mandate

Vinge advises Bygghemma in connection with acquisition of Hemfint

February 26, 2020

Vinge has advised Bygghemma Sverige AB in connection with the acquisition of 84 per cent of the shares in Hemfint Kristianstad AB for a fixed purchase price regarding 51 per cent of the shares, an earn-out based purchase price regarding 33 per cent of the shares over a 3-year period as well as an option to acquire the remaining shares within 3-4 years.

Bygghemma is the leading online based European supplier of products and services within DIY and home furnishings. In 2019, Bygghemma’s turnover was SEK 6.2 billion and the company employs more than 1 500 persons, has its head office in Malmö and is listed on Nasdaq Stockholm, Mid Cap. Hemfint is a fast-growing online provider of doors, windows, bathroom and leisure products in Sweden under its own trademarks and had a turnover of more than SEK 150 million in 2018.

Vinge’s team consisted of partner Kristian Ford together with, among others, associates Niklas Törnell, Tilda Hall, Jessica Salomonsson (commercial property/real estate) and Freja Najafi Kristensen (employment). 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025